Galectin Therapeutics Inc. — Form 10-Q Summary
Business context and reporting period
Development-stage biotechnology company focused on galectin-targeting therapies for fibrotic disease and cancer. This report covers the three months ended March 31, 2014; comparative results are for the three months ended March 31, 2013. The company reported no significant revenue and has operated at a loss since inception.
Financial results and liquidity
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | — |
| Research and development expense | $2.772 million | $1.752 million | +58% |
| General and administrative expense | $2.072 million | $1.456 million | +42% |
| Total operating expenses | $4.844 million | $3.208 million | +51% |
| Net loss | $5.110 million | $3.203 million | Loss increased |
| Net loss applicable to common stockholders | $5.408 million | $3.472 million | Loss increased |
| Basic and diluted loss per share | $0.27 | $0.22 | Loss per share increased |
| Net cash used in operating activities | $3.619 million | $2.423 million per cash-flow statement | Higher use |
At March 31, 2014, cash and cash equivalents were $36.594 million, compared with $10.489 million at December 31, 2013. Financing activities provided $30.124 million, including $28.178 million of net proceeds from common-stock issuance and $1.946 million from warrant and option exercises. Investing activities used $0.400 million for the company’s investment in Galectin Sciences, LLC.
Total liabilities were $1.937 million. The balance sheet reported no long-term debt, but included redeemable convertible preferred stock with carrying values totaling approximately $6.696 million and stated redemption values of approximately $11.130 million. Stockholders’ equity was $28.266 million at March 31, 2014.
Operating margins are not meaningful because the company had no revenue. Stock-based compensation was $1.648 million in Q1 2014, compared with $0.852 million in Q1 2013, and represented a significant portion of operating expenses.
Material changes versus the prior comparable period
- Research and development expense increased $1.020 million, primarily from Phase 1 clinical-trial activities, manufacturing costs in preparation for a potential Phase 2 program, preclinical work, and higher stock-based compensation.
- General and administrative expense increased $0.616 million, principally because of higher stock-based compensation and legal expenses related to litigation involving the former chief executive officer.
- Common shares outstanding increased to 21.906 million at March 31, 2014 from 18.387 million at December 31, 2013, primarily reflecting the January and February 2014 equity issuance.
- The company completed its prior at-the-market equity program by issuing 2.664 million common shares for approximately $28.178 million of net proceeds.
- In January 2014, the company formed Galectin Sciences, LLC with SBH Sciences, Inc. Each party owns 50%. The company invested $0.400 million and recognized a $0.270 million equity-method loss, including its share of an immediate non-cash charge for contributed in-process research and development.
Guidance, outlook, risks, contingencies, and unusual items
Management stated that the $36.6 million of unrestricted cash at March 31, 2014 was sufficient to fund operations through 2015, although continued funding after that point depends on additional financing or achieving profitable operations. The company filed a new shelf registration permitting up to $100 million of additional common-stock offerings and maintained flexibility to issue up to $30 million under an at-the-market arrangement.
GR-MD-02 is the lead candidate for NASH with advanced liver fibrosis and cancer immunotherapy. The first cohort of its Phase 1 NASH trial was completed without reported serious adverse events, and initial safety, tolerability, and biomarker results were presented on March 31, 2014. Enrollment in the second cohort was completed in April 2014, with results expected around the end of July 2014. Subject to Phase 1 results, management expected to begin a Phase 2 trial in late 2014 or early 2015, with initial Phase 2 results then planned for the first half of 2016. These are forward-looking expectations and are subject to clinical, regulatory, financing, and enrollment risks.
The company continues to face substantial risks typical of an early-stage biotechnology issuer, including no product revenue, recurring losses, dependence on external capital, clinical-trial and regulatory uncertainty, intellectual-property risks, competition, reliance on third parties, and potential inability to obtain financing on favorable terms.
A $1.000 million severance obligation related to former CEO David Platt remained accrued. The company was delaying payment pending arbitration seeking rescission or reformation of the separation agreement. The former CEO’s appeal of a related lawsuit dismissal was denied on April 14, 2014. The ultimate outcome of the company’s arbitration remained uncertain and could affect the accrued liability.
The filing contains a cash-flow comparison inconsistency: the cash-flow statement reports Q1 2013 operating cash use of $2.423 million, while MD&A states $1.486 million. The filing text does not explain the difference.
Most important facts for investors to verify
- Verify the reported cash runway through 2015 against current clinical-trial spending, planned Phase 2 costs, and potential financing needs.
- Reconcile the Q1 2013 operating cash-flow figures of $2.423 million in the statement and $1.486 million in MD&A.
- Assess dilution from 21.906 million shares outstanding, 5.506 million warrants, 3.365 million options, and approximately 2.550 million shares issuable upon preferred-stock conversion.
- Evaluate clinical progress and the timing and results of the GR-MD-02 Phase 1 and anticipated Phase 2 programs.
- Monitor the $1.000 million former-CEO severance contingency and the outcome of the company’s arbitration.
- Confirm the redemption and liquidation terms of the redeemable convertible preferred stock and the company’s ability to raise additional capital.